

hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on November 22, 2002

P&G Case 8819

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

Patricia Lee Christon, et al. Serial No. 10/025,059

Absorbent Article

Filed December 19, 2001

Confirmation No. 6014

Group Art Unit 3761

Examiner

INFORMATION DISCLOSURE STATEMENT

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

Dear Sir:

For

TECHNOLOGY CENTER R3700

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

### 1. 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

#### 2. 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

# 3. [X] 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

## THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

- (a) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that <u>both</u> a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.
- (b) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.
- (c) The Notification of Acceptance of this Application Under 35 U.S.C. §371 does <u>not</u> indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.
- 4.  $\begin{bmatrix} 37 \text{ C.F.R. } & 1.97 & (b)(4) \end{bmatrix}$  (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. [] <u>Information to be Considered with CPA Filing</u>. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. [] 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & befor
Final Office Action or Notice of Allowance)
This information disclosure statement is being submitted under 37 C.F.R. §1.97(c).
Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37
C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., Ex parte
Quayle) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R.
§1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480
in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to
facilitate the charging of the fee.
ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:
(1) Copies of the cited references were previously cited by or submitted to the USPTO in
prior application Case No, U.S. Patent Application Serial No, filed Applicants claim
priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not
provided with this Statement, pursuant to 37 C.F.R. §1.98(d).
OR
[X] (2) Copies of the cited documents are enclosed.
OR
[] (3) Copies of all said documents, except document No.'s, were submitted and
considered in parent application U.S. Patent Application Serial No, filed
Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of
document No.'s are not provided with this Statement, pursuant to 37 C.F.R.
§1.98(d). Copies of document No.'s are enclosed. It is respectfully requested that
the cited documents be carefully considered by the Examiner and made of record in this case.

[] (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

[] (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.

### []Additional information is attached.

Respectfully submitted,

Roddy M. Byrlock
Attorney or Agent for Applicant(s)
Registration No. 37,290
(513) 634-0870

Date: November 22, 2002

Customer No. 27752

(IDS.doc) (Last Revised 12/7/01)

PTO/SB08A (10-01) Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required espond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

	s it contains a valid OMB control number
COMPI	LETE IF KNOWN
Application Number	10/025,059 NOV
Confirmation Number	December 19, 2001
Filing Date	December 19, 2001
First Named Inventor	Patricia Lee Christon, et al.
Group Art Unit	3761
Examiner Name	
Attorney Docket Number	8819

### **U. S. PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-4,908,026	03-13-1990	Sukiennik	
		US-4,909,879	03-20-1990	Ball	
		US-5,401,267	03-28-1995	Couture-Dorschner	
		US-5,454,800	10-03-1995	Hirt	
		US-5,458,590	10-17-1995	Schleinz	
		US-5,566,616	10-22-1996	Schleinz	
		US-5,562,037	10-08-1996	Schleinz	
		US-5,683,752	11-04-1997	Popp	
		US-5,766,389	06-16-1998	Brandon	<del> </del>
		US-5,818,719	10-06-1998	Brandon	<u> </u>

### **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DOCUMENT  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
		EP 0 605 730 A1 1	07-13-1994	Kasaki		
		EP 0 774 946 B1 s	05-28-1997	Hirt		
		EP 0 794 280 A2 »	09-10-1997	Hautojarvi		
		EP 1 057 465 A1	12-06-2000	Hirt		
		EP 1 199 057 A1	04-24-2002	Machida	· · · · · · · · · · · · · · · · · · ·	
		EP 1 203 571 A2 ;	05-08-2002	Brown		
		WO 94/26221 A1 💉	11-24-1994	Hirt		
		WO 01/32318 A2	05-10-2001	Sharma		

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
EXAMINE	₹	DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.